microRNA replacement in malignant pleural mesothelioma

Dr Glen Reid - The University of Sydney, Sydney, Australia
microRNA replacement in malignant pleural mesothelioma ( Dr Glen Reid - The University of Sydney, Sydney, Australia )
26 Jun 2014

Investigating anticarcinogenic compounds as an alternative to chemo

Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy
Investigating anticarcinogenic compounds as an alternative to chemo ( Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy )
6 Jun 2014

Comment: Advances in lung cancer presented at ASCO 2014

Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland
Comment: Advances in lung cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )
1 Jun 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014

Intratumour heterogeneity in renal and lung cancer

Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK
Intratumour heterogeneity in renal and lung cancer ( Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK )
6 May 2014

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC
Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )
1 May 2014

Promising advances in the treatment of lung cancer using MK-3475 as an immune checkpoint inhibitor

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
Promising advances in the treatment of lung cancer using MK-3475 as an immune checkpoint inhibitor ( Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA )
1 May 2014

Benefits found for lung cancer patients with high levels of PD-L1 with MK-3475 treatment

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
Benefits found for lung cancer patients with high levels of PD-L1 with MK-3475 treatment ( Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA )
1 May 2014

Role of genomics in assessing risk, especially in ovarian cancer

Dr Thomas Sellers - Moffitt Cancer Center, Tampa, USA
Role of genomics in assessing risk, especially in ovarian cancer ( Dr Thomas Sellers - Moffitt Cancer Center, Tampa, USA )
1 May 2014

The 1st Immunotherapy of Cancer Conference (ITOC)

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria
The 1st Immunotherapy of Cancer Conference (ITOC) ( Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria )
25 Mar 2014

mRNA-based cancer vaccines

Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh
mRNA-based cancer vaccines ( Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh )
24 Mar 2014